Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents

Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):141-5. doi: 10.1089/oli.1.1998.8.141.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Camptothecin / pharmacology
  • Cell Division / drug effects
  • Cisplatin / pharmacology
  • Colonic Neoplasms / pathology
  • Combined Modality Therapy
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors*
  • Cyclic AMP-Dependent Protein Kinases / genetics
  • Doxorubicin / pharmacology
  • Drug Design
  • Drug Screening Assays, Antitumor
  • Drug Synergism
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / immunology
  • Female
  • Fluorouracil / pharmacology
  • Genetic Therapy*
  • Humans
  • Methotrexate / pharmacology
  • Oligonucleotides, Antisense / chemistry
  • Oligonucleotides, Antisense / pharmacology
  • Oligonucleotides, Antisense / therapeutic use*
  • Ovarian Neoplasms / pathology
  • Paclitaxel / pharmacology
  • Structure-Activity Relationship
  • Thionucleotides / chemistry
  • Thionucleotides / pharmacology
  • Thionucleotides / therapeutic use
  • Tumor Cells, Cultured
  • Vincristine / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Oligonucleotides, Antisense
  • Thionucleotides
  • Vincristine
  • Doxorubicin
  • ErbB Receptors
  • Cyclic AMP-Dependent Protein Kinases
  • Paclitaxel
  • Cisplatin
  • Fluorouracil
  • Camptothecin
  • Methotrexate